Quince Therapeutics (QNCX) Short term Debt (2023 - 2025)

Quince Therapeutics has reported Short term Debt for 3 years, with the latest figure at $18.0 million in Q4 2025.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $18.0 million in Q4 2025; TTM through Dec 2025 was $18.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $18.0 million, changed N/A from the prior year.
• Short term Debt was $18.0 million for Q4 2025 at Quince Therapeutics, up from $17.5 million in the prior quarter.
• The five-year high for Short term Debt was $18.0 million in Q4 2025, with the low at $4.1 million in Q4 2023.
• Average Short term Debt over 3 years is $9.9 million, with a median of $5.0 million recorded in 2024.